Among patients undergoing intermediate-risk chemotherapy regimens, patients with breast cancer were significantly more likely to receive G-CSF as primary prophylaxis than patients with NSCLC, and patients with colorectal cancer were significantly less likely to receive G-CSF as primary prophylaxis. The gene discussed is CSF3; the disease is breast carcinoma.